Development costs, clinical trial advantages, pricing realities, and what makes rare disease gene therapy
Amir Saberi is a stem cell biologist and bioengineer building scalable manufacturing platforms for cell and gene therapies. Trained at the University of Illinois and Johns Hopkins School of Medicine, his work spans genome engineering, iPSC biology, and translational R&D across biotech startups. In 2024, he founded Ambryon, a biological design consulting and manufacturing development firm focused on accelerating the clinical translation of emerging cell and gene therapies.
AAV vectors can package approximately 4.7 kb of genetic cargo. SpCas9 and its regulatory elements require
Designing AAV That Translates: Receptor Biology, Liver De-Targeting, and Route Strategy
| 16 Sep, 2025
Three design principles separate successful AAV programs from those that fail: receptor-aware capsid
Making Base Editors Smaller for Gene Therapy
| 12 Mar, 2025
Discover strategies to reduce base editor size for AAV delivery in gene therapy. This insight explores